Investors looking to support sustainable marine aquaculture and the blue economy need accurate ocean data to make evidence-based decisions and de-risk their financial offerings – but a lack of reliable data might be curtailing their efforts.
Emerging research has shown that nutraceuticals in aquafeed can delay the onset and progress of clinical signs of amoebic gill disease (AGD) in farmed Atlantic salmon.
A side-by-side comparison of conventional and insect-based aquafeed ingredients has found that insect meals and oils come with a larger carbon footprint and require more energy to produce than marine ingredients – but this discrepancy might be short-lived.
Though seaweed operations are diverse – specialising in various species and operating in different economic circumstances – today’s macroalgae practitioners need to stay grounded in science as they work towards their scale and sustainability goals for 2030.
A Dutch startup is planning to integrate aquaculture of seaweed and bivalve shellfish into floating breakwaters – simultaneously protecting fragile coastlines, providing ecosystem services and potentially producing seafood.
According to Ohad Maiman, founder and CEO of The Kingfish Company, they can indeed – although he warned that sustainability is by no means “a free pass” to profitability.
The latest 1810 Ultra syringe design from Socorex brings medical-grade precision to the aquaculture vaccination sector – in the process generating a range of advantages, not least to fish welfare and operator accuracy.
